

**FULL SPECTRUM EXTRACT**



**PRECISE DOSING**



**CONSISTENT FLOWER VARIETY**



## GENERAL PRODUCT INFORMATION:

|                             |                               |                              |                                   |
|-----------------------------|-------------------------------|------------------------------|-----------------------------------|
| <b>PRODUCT NAME:</b>        | KHIROX 25/1                   | <b>SUB-TYPE:</b>             | Hybrid*                           |
| <b>VARIETY:</b>             | White Widow                   | <b>EXTRACTION METHOD:</b>    | CO <sub>2</sub> extraction        |
| <b>THC:</b>                 | 25 mg/ml                      | <b>PLACE OF MANUFACTURE:</b> | Denmark                           |
| <b>CBD:</b>                 | <2 mg/ml                      | <b>CARRIER OIL:</b>          | Medium-chain triglycerides (MCTs) |
| <b>CANNABINOID PROFILE:</b> | Chemotype I (THC-predominant) |                              |                                   |

\*According to the current state of research, no clear active ingredient profiles can be assigned to the subspecies of the cannabis plant (i.e. sativa versus indica). The effect of the different varieties depends mainly on the chemotype, which is determined by the relative amounts of THC and CBD<sup>®</sup>.

## MEDICAL USES



**CINV & ANOREXIA** [1-12,28,29]



**MULTIPLE SCLEROSIS** [9,20-23,28,29]



**SLEEP DISORDERS** [13,14,28-31]



**TOURETTE'S SYNDROME** [24-29]



**CHRONIC PAIN** [15-19,28,29]

For more information about the therapeutic application possibilities, please visit [www.khironmed.co.uk](http://www.khironmed.co.uk).

## REFERENCES

1. Beal, J. E. et al. Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. *J. Pain Symptom Manage.* 14, 7–14 (1997).
2. Badowski, M. E. & Yanful, P. K. Dronabinol oral solution in the management of anorexia and weight loss in AIDS and cancer. *Therapeutics and Clinical Risk Management* vol. 14 643–651 (2018).
3. Nelson, K. A., Walsh, T. D., Deeter, D. & Sheehan, F. A phase II study of delta-9-tetrahydrocannabinol for appetite stimulation in cancer associated anorexia. *J Palliat Care* 10, 14–18 (1994).
4. Walsh, D., Kirkova, J. & Davis, M. P. The efficacy and tolerability of long-term use of dronabinol in cancer-related anorexia: A case series [1]. *Journal of Pain and Symptom Management* vol. 30 493–495 (2005).
5. Bar-Sela, G., Zaiman, D., Semenysty, V. & Ballan, E. The Effects of Dosage-Controlled Cannabis Capsules on Cancer-Related Cachexia and Anorexia Syndrome in Advanced Cancer Patients: Pilot Study. *Integr. Cancer Ther.* 18, 153473541988149 (2019).
6. Brisbois, T. D. et al. Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial. *Ann. Oncol.* 22, 2086–2093 (2011).
7. Volicer L, Stelly M, Morris J, McLaughlin J, V. B. Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease. *Int J Geriatr Psychiatry* 12, 913–9 (1997).
8. Wilson MM, Philpot C, M. J. Anorexia of aging in long term care: is dronabinol an effective appetite stimulant?--a pilot study. *J Nutr Heal. Aging* 11, 195–8 (2007).
9. Whiting, P. F. et al. Cannabinoids for medical use: A systematic review and meta-analysis. *JAMA - Journal of the American Medical Association* vol. 313 2456–2473 (2015).
10. Parker, L. A., Rock, E. M., & Limebeer, C. L. Regulation of nausea and vomiting by cannabinoids. *British Journal of Pharmacology* vol. 163 1411–1422 (2011).
11. Meiri, E. et al. Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. *Curr. Med. Res. Opin.* 23, 533–543 (2007).
12. Hernandez, S. L., Sheynar, I., Stover, K. T. & Stewart, J. T. Dronabinol Treatment of Refractory Nausea and Vomiting Related to Peritoneal Carcinomatosis. *Am. J. Hosp. Palliat. Med.* 32, 5–7 (2015).
13. Woodward, M. R., Harper, D. G., Stolyar, A., Forester, B. P. & Ellison, J. M. Dronabinol for the treatment of agitation and aggressive behavior in acutely hospitalized severely demented patients with noncognitive behavioral symptoms. *Am. J. Geriatr. Psychiatry* 22, 415–419 (2014).
14. Walther, S., Mahlberg, R., Eichmann, U. & Kunz, D. Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia. *Psychopharmacology (Berl.)* 185, 524–528 (2006).
15. Haroutunian, S., Rosen, G., Shouval, R. & Davidson, E. Open-label, add-on study of tetrahydrocannabinol for chronic nonmalignant pain. *J. Pain Palliat. Care Pharmacother.* 22, 213–217 (2008).
16. Boychuk, D. G., Goddard, G., Mauro, G. & Orellana, M. F. The Effectiveness of Cannabinoids in the Management of Chronic Nonmalignant Neuropathic Pain: A Systematic Review. *J. Oral Facial Pain Headache* 29, 7–14 (2015).
17. Konrad, C. et al. Tetrahydrocannabinol (Delta 9-THC) treatment in chronic central neuropathic pain and fibromyalgia patients: Results of a multicenter survey. *Anesthesiology Research and Practice* vol. 2009 (2009).
18. Narang, S. et al. Efficacy of Dronabinol as an Adjuvant Treatment for Chronic Pain Patients on Opioid Therapy. *J. Pain* 9, 254–264 (2008).
19. Roberts, J. D., Gennings, C. & Shih, M. Synergistic affective analgesic interaction between delta-9- tetrahydrocannabinol and morphine. *Eur. J. Pharmacol.* 530, 54–58 (2006).
20. Rice, J. & Cameron, M. Cannabinoids for Treatment of MS Symptoms: State of the Evidence. *Current Neurology and Neuroscience Reports* vol. 18 (2018).
21. Hagenbach, U. et al. The treatment of spasticity with Δ9-tetrahydrocannabinol in persons with spinal cord injury. *Spinal Cord* 45, 551–562 (2007).
22. van Amerongen, G. et al. Effects on Spasticity and Neuropathic Pain of an Oral Formulation of Δ9-tetrahydrocannabinol in Patients With Progressive Multiple Sclerosis. *Clin. Ther.* 40, 1467–1482 (2018).
23. Svendsen, K. B., Jensen, T. S. & Bach, F. W. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. *BMJ* 329, 253 (2004).
24. Müller-Vahl, K. R. et al. Treatment of Tourette's syndrome with Δ9-tetrahydrocannabinol (THC): A randomized crossover trial. *Pharmacopsychiatry* 35, 57–61 (2002).
25. Müller-Vahl, K. R. et al. Treatment of tourette syndrome with delta-9-tetrahydrocannabinol (Δ9-THC): No influence on neuropsychological performance. *Neuropsychopharmacology* 28, 384–388 (2003).
26. Müller-Vahl, K. R. Treatment of Tourette syndrome with cannabinoids. *Behav. Neurol.* 27, 119–24 (2013).
27. Hasan, A. et al. Oral Δ9-tetrahydrocannabinol improved refractory Gilles de la Tourette syndrome in an adolescent by increasing intracortical inhibition: A case report. *J. Clin. Psychopharmacol.* 30, 190–192 (2010).
28. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. The National Academies Press (2017).
29. Health Canada. Information for Healthcare Professionals: Cannabis and the Cannabinoids (2013).
30. Choi, S., Huang, B. C. & Gamaldo, C. E. Therapeutic Uses of Cannabis on Sleep Disorders and Related Conditions. *Journal of Clinical Neurophysiology* vol. 37 39–49 (2020).
31. Mondino, A. et al. Acute effect of vaporized Cannabis on sleep and electrocortical activity. *Pharmacol. Biochem. Behav.* 179, 113–123 (2019).
32. Piomelli D, Russo EB. The Cannabis sativa Versus Cannabis indica Debate: An Interview with Ethan Russo, MD. *Cannabis Cannabinoid Res.* 2016 Jan 1;1(1):44-46.